Onconetix (ONCO) Liabilities and Shareholders Equity (2021 - 2026)

Onconetix (ONCO) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $14.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 21.0% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $78.6 million (up 40.7% YoY), while the FY2025 annual figure was $24.9 million, down 11.55% from the prior year.
• Liabilities and Shareholders Equity retreated to $14.8 million in Q1 2026 per ONCO's latest filing, from $24.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $87.5 million in Q4 2023 and bottomed at $860204.0 in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $23.3 million across 5 years, with a median of $19.3 million in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity soared 10074.1% — and 2024, when it tumbled 76.47%.
• Onconetix's Liabilities and Shareholders Equity stood at $860204.0 in 2022, then jumped by 10074.1% to $87.5 million in 2023, then slumped by 67.8% to $28.2 million in 2024, then retreated by 11.55% to $24.9 million in 2025, then sank by 40.5% to $14.8 million in 2026.
• Business Quant data shows ONCO's Liabilities and Shareholders Equity at $14.8 million in Q1 2026, $24.9 million in Q4 2025, and $19.7 million in Q3 2025.